Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ischemic Cerebral Stroke - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Ischemic Cerebral Stroke - Pipeline Review, H1 2015', provides an overview of the Ischemic Cerebral Stroke's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemic Cerebral Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Cerebral Stroke and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemic Cerebral Stroke - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemic Cerebral Stroke and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemic Cerebral Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ischemic Cerebral Stroke pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemic Cerebral Stroke - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemic Cerebral Stroke pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Ischemic Cerebral Stroke Overview 6 Therapeutics Development 7 Pipeline Products for Ischemic Cerebral Stroke - Overview 7 Pipeline Products for Ischemic Cerebral Stroke - Comparative Analysis 8 Ischemic Cerebral Stroke - Therapeutics under Development by Companies 9 Ischemic Cerebral Stroke - Therapeutics under Investigation by Universities/Institutes 10 Ischemic Cerebral Stroke - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Ischemic Cerebral Stroke - Products under Development by Companies 13 Ischemic Cerebral Stroke - Products under Investigation by Universities/Institutes 14 Ischemic Cerebral Stroke - Companies Involved in Therapeutics Development 15 Neurotec Pharma SL 15 Stempeutics Research Private Limited 16 Ischemic Cerebral Stroke - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 BSc-2118 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 NTKC-005 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Recombinant Peptide for Ischemic Cerebral Stroke - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Recombinant Protein for Ischemic Cerebral Stroke - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Stempeucel - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Ischemic Cerebral Stroke - Recent Pipeline Updates 34 Ischemic Cerebral Stroke - Discontinued Products 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables
Number of Products under Development for Ischemic Cerebral Stroke, H1 2015 7 Number of Products under Development for Ischemic Cerebral Stroke - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Products under Investigation by Universities/Institutes, H1 2015 14 Ischemic Cerebral Stroke - Pipeline by Neurotec Pharma SL, H1 2015 15 Ischemic Cerebral Stroke - Pipeline by Stempeutics Research Private Limited, H1 2015 16 Assessment by Monotherapy Products, H1 2015 17 Number of Products by Stage and Target, H1 2015 19 Number of Products by Stage and Mechanism of Action, H1 2015 21 Number of Products by Stage and Route of Administration, H1 2015 23 Number of Products by Stage and Molecule Type, H1 2015 25 Ischemic Cerebral Stroke Therapeutics - Recent Pipeline Updates, H1 2015 34 Ischemic Cerebral Stroke - Discontinued Products, H1 2015 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.